Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma

  • J Chromatogr Sci. 2026 Feb 13;64(3):bmag004. doi: 10.1093/chromsci/bmag004.
Yuan Chen  1 ,  Tolulope Adebusuyi  1 ,  Edwina Oppong  1 ,  Edidiong Abraham  1 ,  Yen Maroney Lawrence  1 ,  Jing Ma  1 ,  Dong Liang  1 ,  San L Pham  2 ,  Frank E McDonald  2 ,  Alira Danaher  3 ,  Daqing Wu  3 ,  Huan Xie  1
Affiliations
  • 1. College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
  • 2. Department of Chemistry, Emory University, 1515 Dickey Dr., Atlanta, GA 30322 USA.
  • 3. Center for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, 223 James P Brawley Dr SW, Atlanta, GA 30314, USA.
PMID: 41686531 DOI: 10.1093/chromsci/bmag004
Abstract

SLP-1A6 is a nicardipine-derived analog that modulates the embryonic ectoderm development/Enhancer of Zeste Homolog 2 axis and holds promise as novel therapeutics for castration-resistant prostate Cancer (PCa). We report here the development and validation of a robust, sensitive and specific LC-MS/MS method for quantifying SLP-1A6 in rat plasma, as part of its preclinical investigation. The method demonstrated excellent linearity, precision, accuracy, extraction recovery and stability with negligent matrix effect over a 5-2500 ng/mL concentration range. The method was successfully applied for a single intravenous dose pharmacokinetic (PK) study in adult male Sprague-Dawley rats and the resulting PK parameters were comparable to those of nicardipine, indicating that SLP-1A6 retains the favorable PK profile of the parent compound while offering in vivo efficacy for chemoresistant PCa. These findings support the further preclinical development of SLP-1A6 to overcome chemoresistance in PCa.

Products